On June 24, 2025, Nektar Therapeutics confirmed it has regained compliance with Nasdaq's minimum bid price rule after its stock maintained a closing price of at least $1.00 for 10 consecutive business days, resolving a previous non-compliance notice received on April 3, 2025.